{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:29:58Z","timestamp":1788852598004,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Oncohistones represent compelling evidence for a causative role of epigenetic perturbations in cancer. Giant cell tumours of bone (GCTs) are characterised by a mutated histone H3.3 as the sole genetic driver present in bone-forming osteoprogenitor cells but absent from abnormally large bone-resorbing osteoclasts which represent the hallmark of these neoplasms. While these striking features imply a pathogenic interaction between mesenchymal and myelomonocytic lineages during GCT development, the underlying mechanisms remain unknown. We show that the changes in the transcriptome and epigenome in the mesenchymal cells caused by the H3.3-G34W mutation contribute to increase osteoclast recruitment in part via reduced expression of the TGF\u03b2-like soluble factor, SCUBE3. Transcriptional changes in\n                    <jats:italic>SCUBE3<\/jats:italic>\n                    are associated with altered histone marks and H3.3\n                    <jats:sup>G34W<\/jats:sup>\n                    enrichment at its enhancer regions. In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation. These findings provide a mechanism by which GCTs undergo differentiation in response to denosumab, a drug that depletes the tumour of osteoclasts. In contrast,\n                    <jats:italic>hTERT<\/jats:italic>\n                    alterations, commonly found in malignant GCT, result in the histone-mutated neoplastic cells being independent of osteoclasts for their proliferation, predicting unresponsiveness to denosumab. We provide a mechanism for the initiation of GCT, the basis of which is dysfunctional cross-talk between bone-forming and bone-resorbing cells. The findings highlight the role of tumour\/microenvironment bidirectional interactions in tumorigenesis and how this is exploited in the treatment of GCT.\n                  <\/jats:p>","DOI":"10.1038\/s41418-022-01031-x","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T06:04:04Z","timestamp":1663913044000},"page":"2459-2471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone"],"prefix":"10.1038","volume":"29","author":[{"given":"Lucia","family":"Cottone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Ligammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Mao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-6067","authenticated-orcid":false,"given":"Helen J.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9032-3828","authenticated-orcid":false,"given":"Stephen","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Amary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tirabosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Haendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-9853","authenticated-orcid":false,"given":"Joachim L.","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-717X","authenticated-orcid":false,"given":"Javier","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agamemnon E.","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-8116","authenticated-orcid":false,"given":"Paolo","family":"Salomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-1303","authenticated-orcid":false,"given":"Adrienne M.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"1031_CR1","volume-title":"WHO classification of soft tissue and bone tumours","author":"Editorial Board.","year":"2020","unstructured":"Editorial Board. WHO classification of soft tissue and bone tumours. Lyon, France: IARC; 2020."},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","volume":"45","author":"S Behjati","year":"2013","unstructured":"Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479\u201382.","journal-title":"Nat Genet."},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/path.5537","volume":"252","author":"MW Fittall","year":"2020","unstructured":"Fittall MW, Lyskj\u00e6r I, Ellery P, Lombard P, Ijaz J, Strobl AC, et al. Drivers underpinning the malignant transformation of giant cell tumour of bone. J Pathol. 2020;252:433\u201340.","journal-title":"J Pathol"},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04161-1","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Cheng D, Lian C, Liu Y, Luo W, Wang Y, et al. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone. Cell Death Dis. 2021;12:1\u201310.","journal-title":"Cell Death Dis"},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13205119","volume":"13","author":"RG Forsyth","year":"2021","unstructured":"Forsyth RG, Kren\u00e1cs T, Athanasou N, Hogendoorn PCW. Cell biology of giant cell tumour of bone: Crosstalk between m\/wt nucleosome H3.3, telomeres and osteoclastogenesis. Cancers. 2021;13:1\u201318.","journal-title":"Cancers"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","volume":"11","author":"D Thomas","year":"2010","unstructured":"Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275\u201380.","journal-title":"Lancet Oncol"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18955-y","volume":"11","author":"P Lutsik","year":"2020","unstructured":"Lutsik P, Baude A, Mancarella D, \u00d6z S, K\u00fchn A, Toth R, et al. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone. Nat Commun. 2020;11:1\u201337.","journal-title":"Nat Commun"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165\u201376.","journal-title":"Cell."},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1101\/gad.238873.114","volume":"28","author":"CM Weber","year":"2014","unstructured":"Weber CM, Henikoff S. Histone variants: dynamic punctuation in transcription. Genes Dev. 2014;28:672\u201382.","journal-title":"Genes Dev"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226\u201331.","journal-title":"Nature."},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"27354","DOI":"10.1073\/pnas.2006076117","volume":"117","author":"SU Jain","year":"2020","unstructured":"Jain SU, Khazaei S, Marchione DM, Lundgren SM, Wang X, Weinberg DN, et al. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci USA. 2020;117:27354\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/2159-8290.CD-20-0461","volume":"10","author":"S Khazaei","year":"2020","unstructured":"Khazaei S, De Jay N, Deshmukh S, Hendrikse LD, Jawhar W, Chen CCL, et al. H3.3 G34W promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in giant cell tumor of bone. Cancer Disco. 2020;10:1968\u201387.","journal-title":"Cancer Disco"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/PAS.0000000000001555","volume":"45","author":"DA Kerr","year":"2021","unstructured":"Kerr DA, Brcic I, Diaz-Perez JA, Shih A, Wilky BA, Pretell-Mazzini J, et al. Immunohistochemical characterization of giant cell tumor of bone treated with denosumab: support for osteoblastic differentiation. Am J Surg Pathol. 2021;45:93\u2013100.","journal-title":"Am J Surg Pathol"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev-physiol-021119-034425","volume":"82","author":"NA Sims","year":"2020","unstructured":"Sims NA, Martin TJ. Osteoclasts provide coupling signals to osteoblast lineage cells through multiple mechanisms. Annu Rev Physiol. 2020;82:507\u201329.","journal-title":"Annu Rev Physiol"},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1038\/onc.2011.85","volume":"30","author":"YY Wu","year":"2011","unstructured":"Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, et al. SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene. 2011;30:3682\u201393.","journal-title":"Oncogene."},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"37485","DOI":"10.1074\/jbc.M405912200","volume":"279","author":"BT Wu","year":"2004","unstructured":"Wu BT, Su YH, Tsai MT, Wasserman SM, Topper JN, Yang RB. A novel secreted, cell-surface glycoprotein containing multiple epidermal growth factor-like repeats and one CUB domain is highly expressed in primary osteoblasts and bones. J Biol Chem. 2004;279:37485\u201390.","journal-title":"J Biol Chem"},{"key":"1031_CR17","first-page":"4035","volume":"6","author":"H Fuchs","year":"2016","unstructured":"Fuchs H, Sabrautzki S, Przemeck GKH, Leuchtenberger S, Lorenz-Depiereux B, Becker L, et al. The first Scube3 mutant mouse line with pleiotropic phenotypic alterations. G3. 2016;6:4035\u201346.","journal-title":"G3"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajhg.2020.11.015","volume":"108","author":"YC Lin","year":"2021","unstructured":"Lin YC, Niceta M, Muto V, Vona B, Pagnamenta AT, Maroofian R, et al. SCUBE3 loss-of-function causes a recognizable recessive developmental disorder due to defective bone morphogenetic protein signaling. Am J Hum Genet. 2021;108:115\u201333.","journal-title":"Am J Hum Genet"},{"key":"1031_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05607-5","volume":"9","author":"HPJ Voon","year":"2018","unstructured":"Voon HPJ, Udugama M, Lin W, Hii L, Law RHP, Steer DL, et al. Inhibition of a K9\/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma. Nat Commun. 2018;9:3142.","journal-title":"Nat Commun"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.CD-12-0426","volume":"3","author":"L Bjerke","year":"2013","unstructured":"Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Disco. 2013;3:512\u20139.","journal-title":"Cancer Disco"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2020.11.012","volume":"183","author":"CCL Chen","year":"2020","unstructured":"Chen CCL, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade AF, et al. Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis. Cell. 2020;183:1617\u201333.e22.","journal-title":"Cell."},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/ard.2009.119396","volume":"69","author":"EF Wagner","year":"2010","unstructured":"Wagner EF. Bone development and inflammatory disease is regulated by AP-1 (Fos\/Jun). Ann Rheum Dis. 2010;69:86\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/hmg\/ddt575","volume":"23","author":"L Zhang","year":"2014","unstructured":"Zhang L, Choi HJ, Estrada K, Leo PJ, Li J, Pei YF, et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet. 2014;23:1923\u201333.","journal-title":"Hum Mol Genet"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.7150\/ijms.25369","volume":"15","author":"M Correa-Rodr\u00edguez","year":"2018","unstructured":"Correa-Rodr\u00edguez M, Rio-Valle JS, Rueda-Medina B. AKAP11 gene polymorphism is associated with bone mass measured by quantitative ultrasound in young adults. Int J Med Sci. 2018;15:999\u20131004.","journal-title":"Int J Med Sci"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMoa0801197","volume":"358","author":"U Styrkarsdottir","year":"2008","unstructured":"Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355\u201365.","journal-title":"N Engl J Med"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/ng.446","volume":"41","author":"F Rivadeneira","year":"2009","unstructured":"Rivadeneira F, Styrk\u00e1rsdottir U, Estrada K, Halld\u00f3rsson BV, Hsu YH, Richards JB, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009;41:1199\u2013206.","journal-title":"Nat Genet"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1008805","volume":"16","author":"ML Doolittle","year":"2020","unstructured":"Doolittle ML, Calabrese GM, Mesner LD, Godfrey DA, Maynard RD, Ackert-Bicknell CL, et al. Genetic analysis of osteoblast activity identifies Zbtb40 as a regulator of osteoblast activity and bone mass. PLoS Genet. 2020;16:1\u201320.","journal-title":"PLoS Genet"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/jbmr.2913","volume":"31","author":"CM Nielson","year":"2016","unstructured":"Nielson CM, Hsu YH. Novel genetic variants associated with increased vertebral volumetric BMD, reduced vertebral fracture risk, and increased expression of SLC1A3 and EPHB2. J Bone Min Res. 2016;31:2085\u201397.","journal-title":"J Bone Min Res"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW, M\u00fcller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340:857\u201361.","journal-title":"Science."},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.aac7272","volume":"352","author":"C Lu","year":"2016","unstructured":"Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science. 2016;352:844\u20139.","journal-title":"Science"},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1038\/sj.onc.1204037","volume":"19","author":"A Raouf","year":"2000","unstructured":"Raouf A, Seth A. Ets transcription factors and targets in osteogenesis. Oncogene. 2000;19:6455\u201363.","journal-title":"Oncogene."},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17:1473\u201380.","journal-title":"Nat Med"},{"key":"1031_CR33","first-page":"1","volume":"7","author":"B Guo","year":"2016","unstructured":"Guo B, Dang L, Qian A, Xiao L, Xu L, Zhang B-T, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Comm. 2016;7:1\u201316.","journal-title":"Nat Comm"},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/PAS.0000000000000859","volume":"41","author":"F Amary","year":"2017","unstructured":"Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41:1059\u201368.","journal-title":"Am J Surg Pathol"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/his.13448","volume":"72","author":"I Kato","year":"2018","unstructured":"Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology. 2018;72:914\u201322.","journal-title":"Histopathology."},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41379-019-0318-5","volume":"32","author":"KI Yoshida","year":"2019","unstructured":"Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K. et al. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. 2019;32:1751\u201361.","journal-title":"Mod Pathol"},{"key":"1031_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","volume":"20","author":"BA Nacev","year":"2020","unstructured":"Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, et al. The epigenomics of sarcoma. Nat Rev Cancer. 2020;20:608\u201323.","journal-title":"Nat Rev Cancer"},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","volume":"35","author":"B Krug","year":"2019","unstructured":"Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, et al. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell. 2019;35:782\u201397.","journal-title":"Cancer Cell"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jmb.2018.04.014","volume":"430","author":"L Shi","year":"2018","unstructured":"Shi L, Shi J, Shi X, Li W, Wen H. Histone H3.3 G34 mutations alter histone H3K36 and H3K27 methylation in cis. J Mol Biol. 2018;430:1562\u20135.","journal-title":"J Mol Biol"},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/cdd.2017.41","volume":"24","author":"A Lampada","year":"2017","unstructured":"Lampada A, O\u2019Prey J, Szabadkai G, Ryan KM, Hochhauser D, Salomoni P. MTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death Differ. 2017;24:1045\u201362.","journal-title":"Cell Death Differ"},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1634\/stemcells.2006-0295","volume":"25","author":"M Yen","year":"2007","unstructured":"Yen M, Chien C-C, Chiu I, Huang H-I, Chen Y-C, Hu H-I, et al. Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: a possible in vitro model of human mesenchymal progenitors. Stem Cells. 2007;25:125\u201331.","journal-title":"Stem Cells"},{"key":"1031_CR43","unstructured":"PromoCell GmbH. Osteoblast differentiation and mineralization. https:\/\/www.promocell.com\/f\/2017\/11\/Osteoblast_Differentiation_and_Mineralization-1.pdf."},{"key":"1031_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/path.4906","volume":"242","author":"PA Hulley","year":"2017","unstructured":"Hulley PA, Bishop T, Vernet A, Schneider JE, Edwards JR, Athanasou NA, et al. Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2. J Pathol. 2017;242:322\u201333.","journal-title":"J Pathol"},{"key":"1031_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s002239900473","volume":"62","author":"JMW Quinn","year":"1998","unstructured":"Quinn JMW, Neale S, Fujikawa Y, McGee JD, Athanasou NA. Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calcif Tissue Int. 1998;62:527\u201331.","journal-title":"Calcif Tissue Int"},{"key":"1031_CR46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/path.4729","volume":"239","author":"S Scheipl","year":"2016","unstructured":"Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, et al. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239:320\u201334.","journal-title":"J Pathol"},{"key":"1031_CR47","doi-asserted-by":"crossref","unstructured":"Cottone L, Eden N, Usher I, Lombard P, Ye H, Ligammari L, et al. Frequent alterations in p16\/CDKN2A identified by immunohistochemistry and FISH in chordoma. J Pathol Clin Res. 2020;6:113\u201323.","DOI":"10.1002\/cjp2.156"},{"key":"1031_CR48","unstructured":"Abcam. Histone extraction protocol. https:\/\/www.abcam.com\/protocols\/histone-extraction-protocol-for-western-blot."},{"key":"1031_CR49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525\u201327.","journal-title":"Nat Biotechnol"},{"key":"1031_CR50","doi-asserted-by":"crossref","unstructured":"Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015;4:1521.","DOI":"10.12688\/f1000research.7563.1"},{"key":"1031_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber WKW, Anders S, L\u00f6nnstedt I, Speed T, Robinson MD, et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1031_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nmeth.3885","volume":"13","author":"N Ignatiadis","year":"2016","unstructured":"Ignatiadis N, Klaus B, Zaugg JB, Huber W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat Methods. 2016;13:577\u201380.","journal-title":"Nat Methods"},{"key":"1031_CR53","doi-asserted-by":"publisher","first-page":"e2981","DOI":"10.21769\/BioProtoc.2981","volume":"8","author":"K Niu","year":"2018","unstructured":"Niu K, Liu R, Liu N. Quantitative ChIP-seq by adding spike-in from another species. Bio-Protoc. 2018;8:e2981.","journal-title":"Bio-Protoc"},{"key":"1031_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"BE Bernstein","year":"2012","unstructured":"Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57\u201374.","journal-title":"Nature."},{"key":"1031_CR55","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0841","volume":"8","author":"HB Maganti","year":"2018","unstructured":"Maganti HB, Jrade H, Cafariello C, Rothberg JLM, Porter CJ, Yockell-Leli\u00e8vre J, et al. Targeting the MTF2\u2013MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy. Cancer Disco. 2018;8:1376\u201389.","journal-title":"Cancer Disco"},{"key":"1031_CR56","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","volume":"32","author":"M Pathania","year":"2017","unstructured":"Pathania M, De Jay N, Maestro N, Harutyunyan AS, Nitarska J, Pahlavan P, et al. H3.3 K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell. 2017;32:684\u2013700.","journal-title":"Cancer Cell"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-01031-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T14:04:16Z","timestamp":1671026656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-01031-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1038\/s41418-022-01031-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.27.474195","asserted-by":"object"}]},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. Study approval. Ethical approval for GCT samples was obtained from the Cambridgeshire 2 Research Ethics Service (reference 09\/H0308\/165) (HTA Licence 12198). Written informed consent was received from participants prior to inclusion in the study. All studies have been conducted according to Declaration of Helsinki principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}